📊 GRVE Key Takeaways
Is GRVE a Good Investment? Thesis Analysis
Groove Botanicals is technically insolvent with negative stockholders' equity of -1.4M against minimal assets of 6.3K, indicating the company is balance-sheet bankrupt. The company burns cash operationally (-75.7K) with near-zero revenue (-8.6K) and no liquidity buffer (1.5K cash), making near-term survival questionable without massive capital injection or operational restructuring.
Fundamentals indicate a distressed micro-cap with negative revenue, persistent operating losses, and severely impaired balance sheet (negative equity, minimal cash). Liquidity and solvency risks are acute, with negative operating cash flow and inadequate interest coverage, leaving little runway without restructuring or dilution.
Why Buy GRVE? Key Strengths
- Revenue shows YoY growth of 31.1% (though from negative base, indicating scale issues)
- Low absolute operating expense base (limited burn in dollars)
- Capex-light operations reduce incremental cash needs
- Slight YoY improvement in revenue trend (from a very weak base)
GRVE Investment Risks to Consider
- Negative stockholders' equity indicates technical insolvency and balance sheet bankruptcy
- Virtually no cash (1.5K) relative to 1.4M liabilities - acute liquidity crisis
- Negative operating cash flow of -75.7K with near-zero revenue demonstrates fundamental business model failure
- Current/Quick ratios of 0.00x indicate inability to meet short-term obligations
- Negative interest coverage (-6.3x) means company cannot service debt from operations
- Minimal asset base (6.3K) provides no cushion for unexpected challenges
- Going-concern risk from negative equity and minimal cash
- Acute liquidity shortfall (current ratio ~0) and high near-term obligations
- Sustained negative operating cash flow and poor interest coverage imply dilution/insolvency risk
Key Metrics to Watch
- Stockholders equity trend - must return to positive to avoid bankruptcy
- Monthly cash burn rate and months of runway remaining
- Revenue stabilization and path to profitability or operating breakeven
- Operating cash flow
- Cash & equivalents and current ratio
GRVE Financial Metrics
💡 AI Analyst Insight
The 1,141.5% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. The current ratio below 1.0x warrants monitoring of short-term liquidity.
GRVE Profitability Ratios
GRVE vs Energy Sector
How GROOVE BOTANICALS INC. compares to Energy sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GRVE Overvalued or Undervalued?
Based on fundamental analysis, GROOVE BOTANICALS INC. has mixed fundamental signals relative to the Energy sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GRVE Balance Sheet & Liquidity
GRVE 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: GROOVE BOTANICALS INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
GRVE Growth Metrics (YoY)
GRVE Capital Allocation
GRVE SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for GROOVE BOTANICALS INC. (CIK: 0000918573)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GRVE
What is the AI rating for GRVE?
GROOVE BOTANICALS INC. (GRVE) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GRVE's key strengths?
Claude: Revenue shows YoY growth of 31.1% (though from negative base, indicating scale issues). ChatGPT: Low absolute operating expense base (limited burn in dollars). Capex-light operations reduce incremental cash needs.
What are the risks of investing in GRVE?
Claude: Negative stockholders' equity indicates technical insolvency and balance sheet bankruptcy. Virtually no cash (1.5K) relative to 1.4M liabilities - acute liquidity crisis. ChatGPT: Going-concern risk from negative equity and minimal cash. Acute liquidity shortfall (current ratio ~0) and high near-term obligations.
What is GRVE's revenue and growth?
GROOVE BOTANICALS INC. reported revenue of $-8.6K.
Does GRVE pay dividends?
GROOVE BOTANICALS INC. does not currently pay dividends.
Where can I find GRVE SEC filings?
Official SEC filings for GROOVE BOTANICALS INC. (CIK: 0000918573) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GRVE's EPS?
GROOVE BOTANICALS INC. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GRVE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, GROOVE BOTANICALS INC. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GRVE stock overvalued or undervalued?
Valuation metrics for GRVE: ROE of N/A (sector avg: 14%), net margin of 1,212.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GRVE stock in 2026?
Our dual AI analysis gives GROOVE BOTANICALS INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is GRVE's free cash flow?
GROOVE BOTANICALS INC.'s operating cash flow is $-75.7K, with capital expenditures of $22.7K. FCF margin is 1,141.5%.
How does GRVE compare to other Energy stocks?
Vs Energy sector averages: Net margin 1,212.2% (avg: 12%), ROE N/A (avg: 14%), current ratio 0.00 (avg: 1.3).